SCHEMBL21591796

SCHEMBL21591796

CCOC(=O)CN1N=C(c2ccc(Cl)cc2)c2c(sc(C)c2C)NC1=S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 1/20 0.40
BRD4 O60885 11/20 0.38
ADORA3 P0DMS8 1/20 0.38
TSPO P30536 1/20 0.38
ENPP2 Q13822 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
FPR1 P21462 1/20 0.38
RAB9A P51151 1/20 0.37
BRD2 P25440 3/20 0.37
BRD3 Q15059 3/20 0.37
BRDT Q58F21 3/20 0.37
CREBBP Q92793 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591797 0.78 BRD4 (0.34) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL22252911 0.77 BRD4 (0.38) TSHRALDH1A1MAPK1BRD4ADORA3
SCHEMBL21591798 0.77 TSHR (0.39) TSHRALDH1A1MAPK1BRD4ADORA3
SCHEMBL28529850 0.77 TSHR (0.39) TSHRALDH1A1MAPK1BRD4ADORA3
SCHEMBL21914872 0.77 BRD4 (0.37) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21594283 0.76 BRD4 (0.54) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21847188 0.72 MEN1 (0.38) ALDH1A1BRD4SMN1; SMN2MAPTHPGD
SCHEMBL23728696 0.71 BRD4 (0.60) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL23728722 0.69 BRD4 (0.58) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8321508 0.69 CYP11B1 (0.39) TSHRALDH1A1MAPK1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708374-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2023-07-25 US disclosed
US-11708374-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2023-07-25 US disclosed
US-11708374-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2023-07-25 US disclosed
EP-3806860-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS Dybly AG (CH) 2021-04-21 EP disclosed
US-20210101909-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2021-04-08 US disclosed
US-20210101909-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2021-04-08 US disclosed
US-10906917-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors DYBLY AG (CH) 2021-02-02 US disclosed
US-10906917-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors DYBLY AG (CH) 2021-02-02 US disclosed
US-20200231598-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2020-07-23 US disclosed
US-20200231598-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) 2020-07-23 US disclosed
WO-2019238557-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS DYBLY AG (CH) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708374-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors BET1, EP300, BICRA TSHR 3124/4885ALDH1A1 4080/4885MAPK1 3490/4885
US-20210101909-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS BET1, EP300, BICRA TSHR 3124/4885ALDH1A1 4080/4885MAPK1 3490/4885
US-10906917-B2 Preparation of condensed triazepine derivatives and their use as BET inhibitors BET1, EP300, BICRA TSHR 3124/4885ALDH1A1 4080/4885MAPK1 3490/4885
US-20200231598-A1 PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS BET1, EP300, BICRA TSHR 3124/4885ALDH1A1 4080/4885MAPK1 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.